A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration

Trial Profile

A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs RO 5303253 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 21 Nov 2011 Actual end date May 2011 added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 NCT reports status as not yet recruting.
    • 26 Nov 2010 Status changed from recruiting to completed as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top